APA (7th ed.) Citation

F, B., P, D., X, W., DA, W., B, Z., J, S., . . . JD, W. (2020). Antibody targeting tumor-derived soluble NKG2D ligand sMIC reprograms NK cell homeostatic survival and function and enhances melanoma response to PDL1 blockade therapy. Journal of hematology & oncology, 13(1), 74. https://doi.org/10.1186/s13045-020-00896-0

Chicago Style (17th ed.) Citation

F, Basher, Dhar P, Wang X, Wainwright DA, Zhang B, Sosman J, Ji Z, and Wu JD. "Antibody Targeting Tumor-derived Soluble NKG2D Ligand SMIC Reprograms NK Cell Homeostatic Survival and Function and Enhances Melanoma Response to PDL1 Blockade Therapy." Journal of Hematology & Oncology 13, no. 1 (2020): 74. https://doi.org/10.1186/s13045-020-00896-0.

MLA (9th ed.) Citation

F, Basher, et al. "Antibody Targeting Tumor-derived Soluble NKG2D Ligand SMIC Reprograms NK Cell Homeostatic Survival and Function and Enhances Melanoma Response to PDL1 Blockade Therapy." Journal of Hematology & Oncology, vol. 13, no. 1, 2020, p. 74, https://doi.org/10.1186/s13045-020-00896-0.